<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04514406</url>
  </required_header>
  <id_info>
    <org_study_id>APERTO CVS</org_study_id>
    <nct_id>NCT04514406</nct_id>
  </id_info>
  <brief_title>APERTO CVS PMCF Study</brief_title>
  <acronym>APERTO CVS</acronym>
  <official_title>APERTO CVS PMCF Study: Drug Coated High Pressure Balloon in Large Veins (re)Stenosis in Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardionovum GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CliPS Service</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>OPIS srl</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cardionovum GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective Observational Single Arm study aimed to assess safety and effectiveness of APERTO&#xD;
      OTW DCB in treating stenosis and restenosis of central veins in dialysis patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The APERTO CVS PMCF study is aimed to evaluate safety and effectiveness of treatment of&#xD;
      central veins (re)stenosis in dialysis patients at short and mid-term follow up, after&#xD;
      treatment with APERTO OTW DCB. Primary endpoint will consist in evaluating the intervention&#xD;
      free period for patients treated with APERTO OTW.&#xD;
&#xD;
      APERTO CVS PMCF Study will also collect data for post-market clinical follow up (PMCF) in a&#xD;
      CE mark device used according to intended use&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinically Assessed Intervention free period at 6 months fup</measure>
    <time_frame>6 months</time_frame>
    <description>clinically assessed intervention free period at 6 months (IFP) defined as dialysis access circuit with no need for clinically driven target lesion repeat intervention for symptom recurrence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural Technical Success</measure>
    <time_frame>intraoperative</time_frame>
    <description>Residual stenosis is no more than 30% after treatment with APERTO OTW measured by angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Clinical Success</measure>
    <time_frame>intraoperative</time_frame>
    <description>After the procedure, haemodialysis access function improved, dialysis function restored, and at least one dialysis session completed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Surgical Success</measure>
    <time_frame>intraoperative</time_frame>
    <description>On the basis of technical success, no major adverse events (MAE) occurred during hospitalization or treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Event</measure>
    <time_frame>12 months follow up</time_frame>
    <description>include death, stroke, thrombosis, allergic reactions, and pulmonary diseases (including pulmonary edema), bleeding complication with the need of transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fistula Flow</measure>
    <time_frame>6 months</time_frame>
    <description>Flow measured with Echo Doppler measured at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recirculation Rate</measure>
    <time_frame>6 months</time_frame>
    <description>Recirculation rate measured at 6 months</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Dialysis; Complications</condition>
  <condition>Central Vein Obstruction</condition>
  <condition>Stenosis</condition>
  <condition>Restenosis</condition>
  <arm_group>
    <arm_group_label>APERTO OTW DCB</arm_group_label>
    <description>Dialysis patients treated with APERTO OTW following (re)stenosis of central veins</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>APERTO OTW DCB</intervention_name>
    <description>Drug Coated Balloon Angioplasty</description>
    <arm_group_label>APERTO OTW DCB</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Dialysis patients with symptoms for stenosis or restenosis of central veins to be treated&#xD;
        with percutaneous angioplasty.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients age &gt;18, no pregnant women, able to perform fup visits, life expectancy &gt; 12&#xD;
             months&#xD;
&#xD;
          -  Dialysis patients undergoing endovascular angioplasty due to clinically symptomatic&#xD;
             stenosis (de novo or restenosis) of the central veins with significant (&gt;50%) stenosis&#xD;
             and diameter&#xD;
&#xD;
          -  The target lesion consists of one or more lesions with a target lesion length of less&#xD;
             than or equal to 100 mm&#xD;
&#xD;
          -  The target blood vessel diameter of the target lesion is between 6.0 and 16.0 mm (in&#xD;
             angiographic or ultrasound evaluation);&#xD;
&#xD;
          -  If there are other non-target lesions, then non-target lesions must be successfully&#xD;
             cured with a not drug coated balloon before treating the target lesion;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with CVS observed and estimated as nonsignificant (&lt; 50% stenosis) or a&#xD;
             vessel &gt; 12 mm in diameter by visual estimation;&#xD;
&#xD;
          -  the patient is now participating in another clinical trial to evaluate drug or medical&#xD;
             device;&#xD;
&#xD;
          -  patient enrolled for this trial before;&#xD;
&#xD;
          -  prenatal pregnancy test result for women of childbearing potential is non-negative,&#xD;
             Lactating woman;&#xD;
&#xD;
          -  patients, who underwent major surgical procedures (such as thoracotomy, craniotomy,&#xD;
             etc.) within 30 days prior to the study;&#xD;
&#xD;
          -  patients scheduled to undergo major surgery (eg, thoracotomy, craniotomy, etc.) within&#xD;
             30 days after enrolment;&#xD;
&#xD;
          -  central veins lesions have been already treated with DCB before&#xD;
&#xD;
          -  presence of a bare metal stent (BMS) or stent graft or vascular access thrombosis in&#xD;
             central veins&#xD;
&#xD;
          -  patients allergic or intolerant to paclitaxel, or contrast media;&#xD;
&#xD;
          -  patients whose life expectancy is less than 1 year&#xD;
&#xD;
          -  presence of Thrombus in central veins&#xD;
&#xD;
          -  tumor compression&#xD;
&#xD;
          -  thoracic inlet syndrome&#xD;
&#xD;
          -  patients implanted with pacing or cardioverter devices with leads&#xD;
&#xD;
          -  any other central line within the target lesion&#xD;
&#xD;
          -  Patients with any contraindications as mentioned in the Instructions for Use (IFU) of&#xD;
             the Investigational Device&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petra Michel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Hochsauerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Lichtenberg, MD, FESC</last_name>
    <role>Study Director</role>
    <affiliation>Klinikum Hochsauerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Petra Michel, MD</last_name>
    <phone>+4902932/952-343926</phone>
    <email>P.Michel@klinikum-hochsauerland.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vivantes Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>10249</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael Burbelko, MD</last_name>
      <email>Michael.Burbelko@vivantes.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St.Franziskus Hospital</name>
      <address>
        <city>Münster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Michel Bosiers, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires Geneve</name>
      <address>
        <city>Geneva</city>
        <state>Geneve</state>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Frederic Glauser, MD</last_name>
      <email>frederic.glauser@hcuge.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital de la Providence</name>
      <address>
        <city>Neuchâtel</city>
        <state>Neuchatel</state>
        <zip>2000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Amine Chouiter, MD</last_name>
      <email>amine.chouiter@h-ne.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 5, 2020</study_first_submitted>
  <study_first_submitted_qc>August 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2020</study_first_posted>
  <last_update_submitted>August 12, 2020</last_update_submitted>
  <last_update_submitted_qc>August 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Coated Balloon</keyword>
  <keyword>Central Veins Stenosis</keyword>
  <keyword>Percutaneous Intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

